Abstract: Background: NS5B polymerase remains an important anti-hepatitis C virus (HCV) drug target. It has been well reported that ligand binding induces large conformational changes in the receptor. Several computational models describing polymerase dynamics have been reported. Various conformational forms have been determined by crystallography and NMR experiments and they suggest the binding of HCV inhibitors in allosteric sites might affect polymerase flexibility.
INTRODUCTION
Hepatitis C virus (HCV) is a member of genus Hepacivirus (Family: Flaviviridae) is a positivestrand RNA virus. In approximately 80% of acutely infected cases, infection progresses into chronic type-dependent responses and high prevalence of undesirable side effects prompt to focus on the development of novel, safer, and effective anti-HCV therapies [4, 5] . Some of the important developments in the available treatment regimen include FDA approved anti-HCV anti-viral drugs such as telaprevir, boceprevir, and simeprevir acting as viral NS3/4A protease or NS5B polymerase inhibitors [6] [7] [8] [9] [10] [11] . In 2014, Harvoni TM (sofosbuvir and ledipasvir), and Viekira Pak TM (ombitasvir, paritaprevir and dasabuvir) were approved by the FDA [12] [13] [14] [15] . In August 2017, Mavyret (Glecaprevir and Pibrentasvir, AbbVie) has been approved by FDA for the treatment of all HCV strains [16] .
The HCV genome size is approximately 9.6 kb long and contains a single long open reading frame encoding a polyprotein of approximately 3,000 amino acids. The structural proteins are located at the N-terminal portion, followed by nonstructural proteins and the genomic HCV (+) strand (RNA) is first copied into (−) strand HCV RNA, which is then used as the template to produce a large number of progeny (+) strand RNA. One of the nonstructural proteins is HCV replicase (NS5B), which contains RNA-dependent RNA polymerase activity (RdRp) and is responsible for replicating the viral RNA [17, 18] . NS5B is a 68-kDa protein that can carry out RNA synthesis on primed RNA template, as well as de novo synthesis of viral RNA in the absence of primer [19] . The detailed mechanism of HCV NS5B RdRp needs to be investigated.
Various studies have been reported based on efficient structure-based virtual screening to identify inhibitory agents for HCV. The various reported computational approaches of structure-based drug design (SBDD) focusing on the primary role of protein flexibility in docking-based studies and can be exploited to aid NS5B-directed HCV drug discovery efforts.
Protein Flexibility
Initial SBDD approaches rely on validation of "lock and key" models but have various limitations. Efforts were focussed on incorporating protein flexibility and mobility based on the "inducedfit" and "conformational selection" for ligandprotein binding. Plasticity is an important characteristic of flexibility and mobility of bioactive molecules and it has been observed in several pharmacologically important proteins [20] [21] [22] [23] . Conformational adoption based on inherent flexibility is an important feature of DNA or RNA targets [24] [25] [26] [27] . Early docking approaches have been developed based on "rigid receptor flexibility". The recent studies suggest an interrelationship between biomolecular recognition processes and flexibility changes which is acknowledged by the "induced-fit" model [27] . The "conformational selection" model suggests the selection of proper conformations by binding of the rapidly interconverting conformational species of the unbound molecules [28, 29] . The "induced-fit" and "conformational selection" are conceptually different but for both models and every receptor-ligand complex, the receptor and ligand conformations have to be specific to fit.
Receptor flexibility and mobility not only influence steric complementarity in molecular recognition but also contribute towards additional energetic and entropic contributions to the binding affinity. The conformational variability of the receptor affects the well organized binding sites and the changes in the receptor flexibility upon complex formation lead to configurational entropy contribution [30] [31] [32] [33] . In some cases, transfer of flexibility to other protein parts leads to less total entropy loss [28, 29, [34] [35] [36] [37] and computing configurational entropies is difficult [38, 39] . It also provides a basis for allosteric regulation with higher selectivity for the modulator [40] and it can be explained by the conformational changes in the receptor [41, 42] . However, in the "modern view of allostery" the modulator changes the population of conformational substrates with different binding or signal transduction properties [28, 29, 43] . This view explains the role of protein flexibility in carrying allosteric information [44] [45] [46] . A thorough understanding and accurate modeling of protein flexibility and mobility are essential to establish the mechanism and identify allosteric pockets for allosteric modulators.
The various computational approaches in SBDD focus on the incorporation of receptor plasticity into docking such as molecular dynamics (MD), graphtheoretical approaches or normal mode approaches and address what can move and how as well as their transformation into a docking algorithm. The accurate expression and influence of protein flexibility on ligand recognition can be expressed with the help of advanced methods (Fig. 1) . Most of these methods focus on ligand-docking improvement and generation of pharmacophore models to search database. The implicit methods have been first used to accommodate small conformation changes [47] where the protein is held fixed and a "soft" scoring function evaluates ligand-receptor fit. They give a small estimate of receptor plasticity but have certain limitations due to size and conformation. Here softdocking is computationally efficient and easy to implement [48, 49] . Various methods have been reported to generate ensembles of protein structures to represent global and local flexibility [50] . Selective docking is a simple method considering partial protein flexibility to address larger conformational changes [51, 52] and various molecular docking programmes have been incorporated which allow defining flexible side-chains in the active site of the protein. While the ensemble docking approach attempts to dock ligand to an ensemble of receptor conformations and provides full flexibility of protein for simulating large-scale conformational changes [53, 54] . In contrast to this, the on-the-fly docking approach treats protein explicitly by generating new protein conformations by altering the protein structure. Many of the on-the-fly methods are related to induced-fit docking, molecular-relaxation docking [55] , collective-degrees-of-freedom docking [56] , four-dimensional docking [57, 58] , compositestructure docking [59, 60] and hybrid docking [61, 62] .
Structural Features of HCV NS5B
The HCV NS5B contains six conserved motifs designated as A-F and is similar to other known RdRps [63] . Several research groups have successfully reported the three-dimensional crystal structure of HCV NS5B and the HCV RdRp has discernable fingers, palm and thumb subdomains (Figs. 2 and 3) . The HCV RdRp has the characteristic encircled active site due to the extensive interactions between the finger and thumb subdomains [64] [65] [66] . These contact restrict the flexibility of the subdomains and may constrain flexibility between the subdomains. Structural analysis of HCV NS5B (J4 strain) has revealed the role of de novo initiation in RNA synthesis, and limited structural changes take place upon nucleotide binding [67] . Structural studies with HCV RdRp genotype 2a indicate the presence of two conformations of the protein even in the absence of template RNA which differ due to the relative orientation of the thumb domain in relation to fingers and palm domains [68] . Both conformations lack RNA and pose a need to study the role of the template RNA towards inducing the same structural change(s). Another unusual feature of NS5B is a 12 amino acid, β-hairpin loop protruding into the active site located at the base of the palm subdomain and interferes with binding to double-stranded RNA due to steric hindrance [69] . The wild-type HCV RdRp is fully capable of primer-dependent RNA synthesis and needs additional factors to prevent primer extension. Guanosine triphosphate (GTP) along with structures within the RdRp helps to prevent primer-extension [70] . The C-terminal tail of NS5B also lines the RNA binding cleft in the active site. The region immediately preceding the C-terminal membrane anchorage domain forms a hydrophobic pocket and interacts extensively with several important structural elements including the β-loop [71, 72] . Deletions of up to 55 residues of the C-terminal tail resulted in increased RdRp activity, suggesting a direct role for the C-terminal tail in RNA synthesis activity and explains regulating role at the active site [70, 73, 74] . The active sites of HCV NS5B and HIV-1 reverse transcriptase are very similar and can be superimposed without significant steric clashes [64] . Soaked NS5B crystals with NTP and GTP have been analysed that revealed catalytic pocket residues and finger-thumb subdomains, respectively. GTP plays a regulatory role in RNA synthesis due to its position and the requirement of higher GTP concentrations to saturate the pocket [77] .
Recombinant NS5B was sufficient to synthesize full-length HCV RNA in vitro [78] [79] [80] [81] [82] and it can also unwind stable secondary and tertiary RNA structures. Though some genome specific recognition was observed, recombinant NS5B largely lacked specificity for binding to HCV RNA [81] . Different RNAs have been analyzed for RdRp activity such as RNA synthesis, the addition of nontemplated nucleotides to the RNA i.e. terminal nucleotidyl transferase (TNTase), and template switch.
HCV NS5B POLYMERASE INHIBITORS
Three specific classes of polymerase inhibitors such as nucleoside analog inhibitors (NIs), nonnucleoside analog inhibitors (NNIs), and pyrophosphate inhibitors (PPI) have been reported [83] [84] [85] [86] [87] [88] [89] [90] . Nucleoside triphosphate (NTP) provides building blocks of nucleic acids along with cell metabolism and regulation [91] . NIs competes with natural nucleoside triphosphate (NTP) counterparts by binding at the enzyme's active site. This class of inhibitors is proposed to interfere with steps involved in RNA synthesis. NNIs bind at the allosteric sites and inhibit polymerase activity during initiation [83] [84] [85] [86] [87] [88] [89] [90] . While the PPI analogs bind at the anchor domain and mimics natural PPI released during the nucleotidyl transfer reaction [92] .
The NIs class has been investigated as clinical candidates against hepatitis B virus, herpes virus, and HIV [93, 94] . NIs are also termed as nonobligate chain terminators as most of the viral DNA polymerase inhibitory NIs with 3´-OH group permit further nucleoside additions and prevent binding/addition of the next nucleoside through steric problems causing termination. Various NIs have entered into clinics. NM107 (2´C-methylcytidine) is a non-obligate chain terminator and inhibits further nucleotide binding [95] and the clinical trials for its prodrug NM283 (Valopicita-bine) have been halted due to toxicity issues in phase IIb [96] . MK0608 (2´C-methyl-7-deazaadenosine) has proved to be effective against different genotypes like other NIs due to the conservation of an active site at a high level [97] . The detection of S282T mutation at the enzyme active site may contribute to resistance to 2´C-methylated derivatives due to a steric clash between methyl groups of inhibitor and the substituted threonine residue [98] .
IDX184, a prodrug of 2´-methylguanosine is clinically active and has effectively suppressed the emergence of viral resistance in combination with non-nucleoside inhibitors (NNIs) [99, 100] . Some other examples of NIs entered in clinical phase are PSI6130 (β-D-2´-deoxy-2´-fluoro-2´C-methylcytidine) [101] , PSI6206 (uridine analog) [102, 103] , PSI7851 [104] , PSI7977 [103] , R7128 (prodrug of cytidine analog) [105] , R1479 (4´-azidocytidine) [106] , and R1626 (prodrug of 4´-azidocytidine) [107] . NIs are promising drugs to target polymerase in all genotypes due to the strict conservation of NS5B active site while the limitations like the need for phosphorylation, a high concentration of competing NTPs in the cell can be solved by prodrug approach [108, 109] .
The alternative polymerase targeting mechanism is provided by NNIs with multiple binding sites i.e. site I and II in the thumb domain and site III and IV in the palm domain. NNI site I inhibitors include benzimidazoles [110] , indoles [111] , BILB-1941 [112] , and BI207127 [113] . While NNI site II inhibitors bind at a shallow hydrophobic pocket at the thumb domain base are: thiophenes [114, 115] , phenylalanines, hydroxypyranones, and pyranoindoles. Site III is located at the inner thumb/palm domain and is close to the active site. Some of the NNI III inhibitors include benzothiadiazines (ANA598) [84, 116] , and acylpyrrolidines (GSK625433) [117] . The other palm domain binding site i.e. site IV is situated in a large hydrophobic pocket and is targeted by benzofurans, HCV-796, and ABT-333 [118] [119] [120] .
The PPI analogs such as 4,5-dihydroxypyrimidine carboxylic acid, α, γ-diketo acids target HCV polymerase [92, [121] [122] [123] [124] and are reported to be effective at initiation and elongation stages of RNA synthesis [121] , and act by competitive inhibition [122] .
Experimental Data on HCV Polymerase Binding
The HCV NS5B complex crystal structures have defined inhibitor binding sites i.e. central or "palm" domain and "thumb" domain according to the binding position [65, 125] . Some examples of "palm" domain PDBs are 1YVF [126] , 2AWZ,25 2AX0, 2AX1 [127] , 2FVC [128] , 2GC8 [129] , 2GIQ, 2IJN [130] , 2QE2, 2QE5 [131] and for ''thumb'' domain PDB code: 1NHU, 1NHV [132] , 1OS5 [133] , 2BRK, 2BRL [111] , 2DXS [134] , 2GIR [135] , 2HAI [136] , 2HWH, 2HWI [137] , 2I1R [138] , 2O5D [139, 133] , 3CIZ, 3CJ0, 3CJ2, 3CJ3, 3CJ4, 3CJ5 [140, 132] , 3BSA, 3BSC and 3BR9 [141] .
Polymerase NNI Binding Sites or Essential Pharmacophore Interactions
The binding modes and interactions of different classes of chemical moieties have shown strong inhibitory activities with different HCV polymerase binding sites and their inspection provides a better insight into the essential residue interactions for each NNI site. The NS5B domain and its key residues are shown in 3D structure format in Fig. ( 
4).
Thumb I: Study of ligand interactions has led to the identification of residues involved in the formation of pocket as MET36, VAL37, ALA396, LEU392, ALA393, ALA395, THR399, ILE424, LEU425, HIS428, PHE429, LEU492, GLY493, VAL494, PRO495, TRP500, and ARG503. The importance of hydrogen bond formation with ARG503 side chain and a hydrogen acceptor from the ligand was highlighted. All structures share the same interaction. Mutations at PRO495 result in the development of resistance towards benzimidazole thumb I inhibitors (Fig. 4) [142] .
Palm II:
The interactions of HCV-796 inhibitor (1, Fig. 5 ) with receptor side chains of SER365 (H-bond) and ARG200 along with arene-cation bond with the aromatic benzene ring of benzofuran nucleus have been analyzed to identify the pharmacophoric features. In PDB ID: 3FQK, ligand forms H-bond with ASN316 and due to the replacement of ASN by CYS, such bonding is absent in 3FQL and suggests H-bonding as an essential interaction. The residues forming pocket are LEU204, LEU314, VAL321, LEU360, ILE363, SER365, ASN369 and the overlapping part is formed by residues MET193, PRO197, ARG200, ASN316, CYS366, SER368, LEU384, MET414, TYR415 and TYR448 (Fig. 5 ).
Palm I:
The inhibitory ligands are categorized according to the binding analysis of three largest chemical classes co-crystallized with protein i.e. class I: benzothiazoles, class II: benzothiadiazines, and class III: benzodiazepines. All the three categories bind differently in the palm I site. The site is located in the proximity of the active site and at the junction of the thumb and palm domains. The  pocket forming residues are GLN184, MET193,  PRO197, ARG200, THR287, SER288, ASN291,  ASN316, GLY317, ASP318, CYS366, SER368,  LEU384, GLY410, ASN411, MET414, TYR415,  GLN446 , ILE447, TYR448, GLY449 and SER556. These residues partially overlap with palm II site in the following residues MET193, PRO197, ARG200, ASN316, CYS366, SER368, LEU384, MET414, TYR415 and TYR448.
Palm III: The inhibitory potential of phenylpropyl-benzamides at the palm III pocket has been reported for a single PDB coordinate and the key interaction residues are TYR195, PRO197, ARG200, LEW384, MET414, TYR415, ASN316, ILE447, TYR452, LEU446, TRP550, and PHE551. The narrow pocket shows two polar interactions with ASN316 and TYR195 (Fig. 5) .
Thumb II:
The thumb II site is distinct from the thumb I site and is formed by the residues LEU419, ARG422, MET423, HIS475, SER476, TYR477, ILE482, VAL485, LEU497, LEU489, ARG501, TRP528, and LYS533. The common polar interactions have been observed with residues SER476, TYR477 and ARG501 [73] .
HCV Genotypes
The molecular structure of HCV polymerase genotype 1b has been revealed in several crystal forms [61] [62] [63] and the 3D structure provides the architecture of its active site. The X-ray diffraction studies have shown that the active site of NS5B polymerase genotype 1b is completely encircled [61] .
The structures for HCV polymerase genotype 2a complexed with thiophene-2-carboxylic acid non-nucleoside inhibitors have been determined [109, 110, 143] . The HCV polymerase genotype 2a containing a C-terminal deletion of 21 amino acid residues and an N-terminal hexahistidine tag have been investigated [65] . For both genotype 2a and 1b, the same right-hand disposition of fingers, palm, and thumb domains has been observed in the 3D crystal structures. The detailed structure of polymerase in form I was found to be different from form II as seen by the structural variations in the loop (Δ1) protruding from the fingers domain comprising Ile11-Ser46 (RMSD 1.82Å). In form I, the Asn24-Leu31 region is a helix while it is part of a small β-hairpin in form II. High degree of flexibility has been observed in the region as seen by the average B-factor in form II and atoms of the Lys20-Thr40 residues as 27.8 Å 2 and 47.7 Å 2 , respectively. In form I, the molecule is comparatively rigid as seen by low B-factors as well as extensive interactions between the extension (Δ1 loop) from the finger domain and the thumb domain of the molecule. The molecule in form I has more intermolecular interactions than the molecule in form II and the H-bonding networks in the Lys20-Thr40 region indicate adoption of different secondary structures by the molecule in this region. The crystal packing interactions indicate very little effect of neighboring molecules on the Lys20-Thr40 region conformation in both the crystal forms. The study provides structural evidence for the contribution of Δ1 loop towards determining the active state of HCV polymerase genotype 2a as well as other RNA polymerases.
The thumb domain shows the largest structural changes between form I and II and there is a rigid body rotation of 7.5° of the thumb domain compared to the finger and palm domains. Previous reports have investigated the movement of thumb domain during formation of the ternary complex in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase [144] which represents closed and open conformations of RdRp in rabbit hemorrhagic virus [145] . The thumb domain consisting of Leu443-Val454, the β-flap region has been proposed to move and interact with RNA during elongation [64] [65] [66] which supports that HCV polymerase genotype 2a has an ensemble of conformations. The molecule in crystal form I and form II are in closed (active) and open (inactive) conformation, respectively which provides an evidence for the presence of open conformation of NS5B polymerase genotype 2a. The overall structure of HCV polymerase genotype 2a is similar to that of genotype 1b except for some marked structural differences in the thumb domain.
The closed conformation (form I) of NS5B genotype 2a undergoes major conformational/structural changes in three regions i.e. thumb domain, fingers-thumb domains interface, and the β-flap region. For inhibitors 2 and 3 (Fig. 6) , similar conformational changes have been observed. In form II of NS5B, the inhibitor-bound and unbound structures were very similar with the larger Bfactors for protein atoms of the former and thus indicate the flexibility of the inhibitor structure. The major conformational changes have helped to conclude the mechanism of HCV genotype 2a inhibition. The finger domain extension, Δ1 loop moves away from the thumb domain and reduces the inter-fingers-thumb domain interactions and thus perturbates the integrity of the structure. Residues Asn24-Leu31 of the Δ1 loop changes from helical conformation to a small β-hairpin-like structure in the inhibitor-bound structure. Thus the inhibitor binding triggers helix unwinding inducing a shift in the thumb domain relative to the fingers and palm domains. The polymerase gets "locked" into form II in the presence of inhibitor and is incapable of polymerization or reverts back to the active form I [68] . 
Simulations of HCV Polymerase: Exploring Flexibility
Non-nuceloside inhibitors (NNIs) have been developed and some of them have entered in clinical phase of development [146] . The NNIs interact with one of the four identified allosteric site i.e. thumb pocket I and II and palm pocket I and II which are distinct from the enzyme's active site [147] . Two of the reported NS5B polymerase inhibitors, thiophene-2-carboxylic acid derivative (VX-222, 1) and benzothiazidine derivative (ANA598 or Setrobuvir, 5) are in phase II clinical trials. VX-222 binds to the thumb II pocket and ANA598 (5) binds to the palm I pocket. In vitro studies have identified genotypic mutations resistant to VX-222 (4) i.e. L419M, M423T, and I482L and to ANA598 i.e. M414T, M414L, and G554D and thus could reduce the potency [148, 149] . Davis and Thorpe provided detailed structure and motions of NS5B polymerase by the allosteric mechanism of ligands binding at the thumb domain of the enzyme [150] . Xue et al., have reported an investigation of dynamic binding modes of VX-222 (4) and ANA598 (5) with wild-type polymerase and its mutants to discover the possible mechanism of drug resistance [151] . Mutations alter the binding mode and weaken the polymerase-drug interactions. The binding free energy gets decomposed due to mutation as a result of decreased interaction energy for some important residues. 
(ANA598)
VX-222 (4) and ANA598 (5) cocrystallized with the thumb II allosteric pocket and palm I domain of HCV NS5B polymerase (PDB ID: 2GIR and 3H2L) have shown superimposition for docking poses with the crystal structures of NN3 and YAK, respectively, during molecular docking studies. Based on the interaction between residues, the allosteric pocket for VX-222 (4) has been characterized by residues L392, L419, M423, R422, L474, H475, S476, Y477, I482, V485, L497, R527, and W528. For ANA598 (5) , the  pocket consists of F193, P197, R200, D225, S267,  T287, S288, N291, N316, D318, D319, C366,  L384, S407, N411, M414, Y415, Q446, Y448,  G554 , and S556. Additional MD simulation studies and binding free energy calculation of the build models helped to get deep insight into the mode of binding and the influence of the resistance mutations on the drug binding. Their structural comparison in complex with wild-type and mutant polymerase has shown binding through hydrophobic and hydrogen bond contacts. For VX-222 (4), the overall orientation has shown some key interactions i.e. acid group forms H-bonding with S476 and Y477 main chains, neohexyl and cyclohexyl groups interact with the hydrophobic pocket formed by L419, M423, I482, and L497. In case of ANA598 (5), 4-fluorobenzyl and exocyclic moieties form strong bonds with hydrophobic pocket (P197, C366, M414, Y415, and I447) and Hbonding between benzothiadiazine group and the Q446 side chain. The analysis of root mean square fluctuations (RMSF) for polymerase indicates higher fluctuations in the residues of the mutant as compared to the VX-222 (4) and ANA598 (5) bound wild-type polymerase. Thus the large conformational flexibility of the mutant polymerase allows inhibitors binding but weakens drug-mutant interactions due to conformational changes.
Allosteric Inhibitors to Target Protein Flexibility
To investigate the binding mode of different scaffold inhibitors (6-10, Fig. 7 ) using molecular dynamics simulations, free energy calculation and decomposition have been carried out [152] . For most of the inhibitors, TYR448 plays an important role in the binding through strong hydrogen bonds. In NNIs, the β-hairpin loop is stabilized via critical interactions with TYR448 and thus inhibits the polymerase during initiation and elongation phase [153] . The selectivity is regulated by the hydrophobic pocket formed by PRO197, ARG200, CYS366, MET414, and TYR448. Based on crossdocking, an optimized docking protocol has been presented with a representative protein model and used to screen NCI and Maybridge diversity set libraries. Tyr448 and some other residues like Gln446, Tyr415, Gln449, Arg386 were found to be forming hydrogen bonds with the promising inhibitors. To improve the success rate of virtual screening for HCV NS5B, Lin et al. have examined the 26 3D complex crystal structures from Protein Data Bank [154] . A potent HCV NS5B inhibitor has been identified by structure-based virtual screening of the Maybridge Screening Collection along with in vitro cell-based assay. The docking pose of the 3CJ2 inhibitor shows that the cocrystal inhibitor is located in the thumb and palm domain (Fig. 8) .
The binding mode of isoxazole CS01 i.e. 2-(2-nitro-4-(trifluoromethyl)phenoxy)phenyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylate (11) shows that binding mode differs from the structural effect of nucleoside class (palm domain) and interferes with the allosteric binding of 3CJ2 inhibitor. The therapeutic potential of aurones has been discovered with the identification of aureusidin (12) (3′,4,4′,6-tetrahydroxyaurone, [155] a naturally occurring aurone, which potently inhibits HCV RdRp (IC50 of 5.2 μM). Thumb Pocket I has been identified as the aurone binding site through mutagenic studies and molecular modeling. Based on these preliminary data, we used the aurone scaffold as a template for the design of aurone analogues with potent inhibitory activity on HCV RdRp.
The naturally occurring 2-benzylideneb-enzofuran-3-ones (aurones) has been explored as a new template for non-nucleoside HCV RdRp inhibitors [156] . The RdRp inhibitory activity of 42 aurones and molecular docking studies have been used to determine the binding profile and to predict the range of inhibitory activity. The study identified (Z)-2-((1-butyl-1H-indol-3-yl)methyle-ne)-4,6-dihydroxybenzofuran-3(2H)-one as the most active aurone analogue (IC50 = 2.2 μM) and low toxicity [156] .
Some molecular modeling studies have been carried out with the help of GOLD and Autodock software. For N-alkylindole analogues (Z)-2-(Nalkylindolyl)methylene)-4,6-dihydroxybenzofuran -3(2H)-one) the best pose was derived. Arg503 has been identified as an anchor molecule and the hydrophobic residues i.e. Leu492, Val37, Ala393, Leu392, Ala396, Ala395, Phe429 and Ile424 forming two pockets, maintained both the indole part and the N-alkyl substituent of the ligand. The positive effect of 4′-hydrophobic substituents has been explained. The findings help to validate the docking results and confirmed the weak inhibitory potential of this group of indole derivatives, but the geometries of poses obtained with more efficient compounds were homogeneous and relevant. The strong activities of both 4′-hydroxyl and 4′-hydrophobic compounds could be explained by the good fit of these two subclasses of aurones in the pocket. The hypothetic dual mode of aurone binding to Thumb Pocket I of HCV RdRp was shown by compounds 12 and 13 [156] . Kaushik Basu et al. investigated the potential of coumestan scaffold as clinically relevant anti-HCV NNIs with the help of LQB34 and LQB16 followed by the development of SAR using wedelolactone and synthetic coumastan derivatives (14-18, Fig. 9 ) [157] . For docking the NNI binding sites for tetracyclic indole (PDB ID: 2DXS) [134] , N,N-disubstituted phenylalanine (PDB ID: 1NHU) [132] , and benzothiadiazine (PDB ID: 2FVC) [128] inhibitors have been used and the RMSD (0.827, 0.748, ad 0.297 Å, respectively) confirmed the reliability of the procedure. At the allosteric pocket 1 (binding site for tetracyclic indole), comestanes have shown to be better fit as compared to allosteric pocket 2 (binding site for N,N-disubstituted phenylalanine) and allosteric pocket 3 (binding site for benzothiadiazine). The mechanism of inhibition has been further investigated using the potential allosteric pocket 1 by analyzing the interactions of docked conformations of LQB34, LQB96, LQB16 and LQB93. In case of LQB34, benzofuran moiety was found to be located at the deep hydrophobic pocket (Leu392, Ala395, Ala396, Ile424, Leu425, and His495). Coumarin moiety interacts with Val494, pro495, and Trp500 along with electrostatic interactions in the entire shallow-binding pocket of NS5B. The SAR study concluded that hydrophobicity is an important parameter and reduced-RdRp activity is directed towards coumastan binding to the NS5B. Coumastans inhibit NS5B at an early step during the initiation of RNA synthesis and crystallographic studies suggest the presence of a relatively shallow-binding site. Docking study has shown that due to lack of rotatable bonds, coumastans do not undergo conformational changes upon binding to the NS5B. The stable complex obtained from the MD simulations validates the binding score. Coumastans can be further optimized at benzofuran and/or coumarin core structure and peripheral OH and -OCH3 groups for better binding at the NS5B active site.
Li et al. compared five different scaffold inhibitors of NS5B polymerase through molecular dynamics simulations, free energy calculation and decomposition with the identification of Tyr448 as an important residue in binding. The deep hydrophobic pocket of Pro197, Arg200, Cys366, Met414, and Tyr448 imparts selectivity [152] .
Pinson et al. have performed virtual screening of some reported phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PI3Kγ) thiazolidinedione inhibitors to target PI3Kα isoform with 12 compounds with sub-micromolar IC50 values [158] . Standard docking procedures do not allow true representation of the protein as they hold the receptor binding site rigidly. Molecular dynamic simulation methods can be simulated by induced fit docking to allow ligand and protein flexibility [159] [160] [161] . Induced fit virtual screening experiments for PI3Kα homology model (2RD0) has improved results showing the influence of specific conformers surrounding key residues on docking results. Structural comparison of the derived models shows close backbone alignment with most variations observed in side-chain orientation.
During transition from initiation to elongation, NS5B may undergo significant conformational changes and is expected to exist in multiple conformations. Manvar et al. used an NTP analog, fluorosulfonyl benzoyl adenosine (FSBA, 19) to map the NTP binding sites on NS5B [162] . FSBA resembles adenosine triphosphate (ATP, 5) and has been previously studied as a probe for nucleotide binding sites in polymerases and kinases [163] [164] [165] [166] [167] [168] [169] [170] [171] . The reactive sulfonyl fluoride group of FSBA resides in the β-and γ-phosphate positions of NTP and reacts with the nucleophile side chain of amino acid residues around nucleotide binding domain (NBD) of the enzyme. The crystal structure of NS5B binds to GTP at the allosteric site (PDB ID: 1GX5) that has been used to derive the most favorable poses by application of induced-fit docking approach. The docking results concluded that residues Arg158, Ser367, Arg386 and Thr390 form primer-site (P-site) to interact with the triphosphate moiety of NTP, H-bonding with His467, Ser470, Asp375, Lys379, Lys209 and hydrophobic interactions with Tyr383, Tyr382, and Val381, stabilizing the ring moieties. The electro-philic sulfonylfluoride moiety of FSBA (19) forms stable covalent linkages identified as tryptic peptide and the position of fluorosulfonylbenzoyl moiety resembles the triphosphate moiety of ATP (20) showing binding with amino acids from the vicinity. The study suggests that the location of reactive sites within the region interacting with NTP substrate and FSBA (19) , irreversibly inactivates RdRp activity of the enzyme. In all the NTPs, the triphosphate moieties share same binding sites and for individual NTP, the binding is guided by the template base. 
(ATP)
Manikrao et al. reported the in silico analysis of some HCV inhibitors using the Molecular Operating Environment dock (MOE-Dock) by Chemical Computing Group Inc. having an advantage of flexible docking integrated with graphical interface and modules such as molecular mechanics, and molecular dynamics [172] . A set of twelve C-3 substituted azapteridine analogs has been docked into the active site of RdRp polymerase (PDB ID: 2gir, Resolution 2.0 Å). The most active analog with 18 conformations and nonpolar hydrophobic interactions indicates flexibility as an important parameter. This analog is surrounded by Trp528, Arg422, Met423, Leu497, Leu474, His475, and Ser476 in the hydrophobic cage but does not show strong interactions (energy = -9.9366). For other analogs, the C-3 substituted phenoxy phenyl group imparts flexibility and energy of conformation (-7.50051) suggests that this substitution does not affect the activity. The rest of the azapteridine analogs show orientation towards hydrophobic cage of receptor and flexibility plays an important role in proper alignment and stability of ligand in the receptor cavity.
The HCV polymerase adopts two major conformations upon inhibitor binding at the allosteric site located in the thumb region [68, 173] . The major difference is a significant shift of α helix T located in the binding site which accounts for thumb binding site plasticity in drug design. Most of the docking programs failed to predict the experimentally observed binding modes of HCV polymerase inhibitors with high accuracy Fig. (9) . Coumestan analogs (15) (16) (17) (18) (19) . [174] . The FITTED 1.0 has been modified to FITTED 1.5 to challenge the poor accuracy due to the flexibility of this protein [175] . The FIT-TED 1.5 version has shown significant accuracy and speed for docking and virtual screening. Two binding sites of HCV polymerase (i.e. allosteric and catalytic site) have been analyzed for validating the accuracy by virtual screening of Maybridge library. Top-scoring compounds were purchased and screened in HCV polymerase assays with the identification of two compounds (IC50 = 7 and 12 μM).
The site flexibility has been accessed by using two inhibitor-bound in-house crystal structures in a "semi-flexible" docking run option available in FITTED 1.5. The key interactions were Hbonding with Tyr477 and Ser476 and two hydrophobic pockets have been targeted [60] . A compound would trap water molecules if binds without filling the deep hydrophobic pocket formed by Met423, Trp528, and Leu419 and desolvation of other hydrophobic pockets defined by Leu419, Ile482 and Leu497 is favored upon binding.
A reported HCV NS5B inhibitor, compound 21 (Valent Pharmaceuticals, in 2006, IC50 = 2.0 μM) has been analyzed using X-ray soaking experiments showing its binding at the "Thumb pocket II" [35] . The observed binding interactions in the allosteric site (PDB code 2HWH) include [137] : C=O, N of the thiazole ring and sulfonamide moiety form Hbonds with backbone -NHs of Tyr477, Ser476 and the basic side chain of Arg501, respectively, The furan and the phenyl rings make hydrophobic contacts with the side chains of Leu 419, Met423, Ile 482, Val485, Leu489, Leu497, and Trp528 of the protein. Additional examination of the inhibitorprotein interactions revealed the need to explore the additional pocket (His475 and Lys533 at the entrance) present in the vicinity [130] . Yan et al. concluded that for a designed inhibitor, interactions with the amino acid residues present at the entrance could represent a new molecular platform to probe this extra pocket [130] . SAR studies for derivatives of thiazolone (21) concluded (i) the essential role of furan moiety coupled to a thiazolone core by sp 2- hybridized carbon linker and acidic sulfonamide moiety, (ii) improved potency with replacement of furan moiety by phenyl groups extended with paraaromatic or non-aromatic heterocycle, pyridyl group linked to the thiazolinone ring. Further modifications are needed in the left and right parts of the lead molecule (21) by replacing furyl ring with arylidene moieties and the introduction of different phenyl substituents, respectively [176] . During docking, all the sulfonamides (22) have shown similar binding poses with the involvement of Ser476 and Tyr477 in H-bonding with nitrogen and carbonyl group of thiazoline ring, respectively, and electrostatic interactions between Arg501 and Lys533. Both the aromatic rings are accommodated in the versatile hydrophobic sub-pocket B (Leu419, Met423, Trp528 and Ile482, Val485, Leu489, Pro496, Leu497) and the inhibitors have no/little influence on their orientation in the binding site and docking scores. Among the sulfanilamide series (22, 23) , some analogs could not bind to the rigid receptor as in both compounds, the thiazoline ring is far from the binding site near Ser476 and Tyr477 and hydrophobic substituents are accommodated less optimally. During induced-fit docking, these compounds have shown a similar pose with an additional slightly shifted thiazoline ring. Significant conformational changes have been observed in the side chain of Arg501 which allow H-bonding to the carbonyl group of the liker and avoid clashes with piperaziyl tail. The higher internal strain, weak H-bond to key residues and lack of interaction with sub-pocket A may attribute to a lower score. 
23
Manfroni et al. performed induced-fit docking on some 6-aminoquinoline derivatives (24) (25) (26) to describe the binding mode of HCV inhibitors with consideration to receptor flexibility upon ligand binding [177] . The crystal structure of NS5B in complex with inhibitor 27 (PDB ID: 3PHE) [178] has been used to validate the docking protocol. The high binding affinity of aminoquinolines for NS5B can be predicted based on Ki values. The most potent derivatives are 11 and 12 having C-7 piperazine-based fragments and the in silico data suggests this series as TSII-NNIs for further studies. 
27
Yu et al. reported a combined molecular modeling study on a series of 193 NS5B polymerase inhibitory 5-hydroxy-2H-pyridazin-3-one derivatives [179] . The compounds having diverse structure and pIC50 values have been investigated by a 40-ns molecular dynamics (MD) simulation and binding free energy calculations and the key amino acid residues were identified in the binding pocket as Tyr448, Ser556, and Asp318 (Figs. 10 and 11) . MD simulations validated rationality as well as remove defects during docking by giving consideration to salvation effect and treating ligand and protein in a flexible way.
For compound 28 (Fig. 11) , no significant difference between docked complex and MD simulation structures has been observed but the complex underwent several translations of rigid rings. The biological activity can be enhanced for novel NS5B inhibitors on the suggested SAR conclusion: (i) Tyr448, Ser556, and Asp318 may be important H-bond binding sites on the NS5B active pocket; (ii) there should be a bulky group at the 2-position and the 6-position of the ring A, whereas the substituent on the substituent at the 6-position of the ring A and the group at the 7′-position of the ring C should be small; (iii) the middle of the substituent at 1,6-position of the ring A and the beginning of the substituent at 7′-position of the ring C should be small; (iv) the substituents at 7′-position of the ring C should be electropositive group, while other parts of the molecule should be with electronegative group; (v) the substituent at 2,6-position of the ring A and the end of the substituent at 7′-position of the ring C should be hydrophobic. while the beginning and the middle of the substituent at 7′-position of the ring C should be hydrophilic; (vi) there should be hydrogenbond-donor groups at the beginning of the substituent at 7′-position of the ring C, hydrogen-bondacceptor groups in the middle of the substituent at 7′-position of the ring C and 5-position of the ring A to have H-bond interactions with the binding pocket of the NS5B. Wei et al. investigated some NS5B polymerase inhibitors by employing virtual screening approach based on the random forest (RB-VS), epharmacophore (PB-VS), and docking based (DB-VS) methods [180] . Binding interactions and pharmacophoric features at the palm I, thumb I and thumb II regions have been explored for InterBioScreen database of 441,574 compounds using six co-crystal structures of HCV NS5B polymerase (PDB ID: 3HHK, 3SKA, 2BRK, 4DRU, 3PHE) [111, 135, 178, [181] [182] [183] . Five compounds with IC50 and EC50 values of 2.01-23.84 μM and 1.61-21.88 μM, respectively, with no cellular toxicity (CC50 > 100 μM) were identified (Fig. 12) when compared with the known inhibitors (Fig. 13) . Compound N2 has best anti-HCV activity with weak cytotoxicity (CC50 = 51.3 μM).
Compounds N1-N4 (Fig. 12, 29-33 ) showed Hbonding with Ser476 in the thumb II region of the NS5B polymerase. The benzene rings of 29, benzoxaole ring and -CF3 group of 30 are directed towards hydrophobic region and C=O of quinolinone in 31 forms H-bond with Tyr477. In 32, carbonyl group of chromanone forms two H-bonds with Leu474 and Arg422 but has weak affinity due to lack of hydrophobic interactions. Sulfuric acid of 33 forms two H-bonds with Tyr448 and Gly449 in the palm region of NS5B and amide NH forms H-bond with Tyr415. The good binding mode of 29-33 with HCV NS5B polymerase suggests the inhibitory bioactivity. 
Development of Resistance
HCV utilizes conformational flexibility as an immunity evasion strategy and thus limited immunogenicity in patients as compared to other enveloped and nonenveloped viruses. The structural flexibility of the antigenic site at amino acid 412 and 423 confirms that this E2 region is not a part of the structured domain [184] . The glycan chain at N 417 requires peptide chain for binding with monoclonal antibody (MAb) 3/11 by adopting an extended conformation. During virus entry, the extended conformation present at the surface and the N-terminal 40 residues within E2 is structurally flexible. The results are in agreement with the previously reported studies for N-terminal 72 residues within E2 [185] and the conformation of E2 ectodomain core front layer is induced by the MAb AR3C binding [186] .
Quantum mechanics and molecular docking studies on a dataset of substituted C5-arylidene rhodanine derivatives have identified some single digit micromolar inhibitors of HCV NS5B polymerase [187] . The SAR study concluded chloro group position on benzylidene ring as selective for NS5B polymerase binding pocket i.e. PP-I and PP-II.
CONCLUSION
The first X-ray crystal structure of myoglobin and hemoglobin proteins has formed the basis of structure-based drug design (SBDD) [188] [189] [190] [191] [192] . For most of the cases of SBDD, only static structures have been given consideration and most molecular modeling studies have recognized the importance of flexibility with the discovery of two different structures of hemoglobin i.e. "tense" and "relaxed" followed by different tertiary structure conformations [193] . All the proteins are inherently flexible and undergo conformational transitions under native state conditions [28, 29, 185, 194, 195] . The standard virtual docking methods considering rigid receptor may give misleading results because in reality, many proteins undergo sidechain and/or backbone movements. Receptor flexibility alters its binding site to complement the shape and binding mode of the ligand i.e. induced fit docking. These assumptions have led to the application of quantum mechanics and induced-fit docking for the development of various HCV NS5B polymerase inhibitors. This enzyme has proved to be challenging and therefore potential ligands with structural diversity have been modified to enhance selectivity and affinity. These observations will be beneficial to the scientific community in the discovery of potential anti-HCV agents. 
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